FDA Approves Novartis' Capmatinib, Foundation Medicine CDx for Metastatic NSCLC

May 06, 2020

|

NEW YORK – The US Food and Drug Administration on Wednesday approved capmatinib (Novartis' Tabrecta) for treatment of patients with metastatic non-small cell lung cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

FDA Approves Novartis' Capmatinib, Foundation Medicine CDx for Metastatic NSCLC

To read the full story....

Breaking News

Guardant Health CDx Wins FDA Approval for First Liquid Biopsy NGS Tumor Profiling Assay

Genentech's Tecentriq, Paclitaxel Combo Fails to Improve PFS in PD-L1-Positive TNBC

Canbridge Pharmaceuticals Receives Marketing Approval in Taiwan for Puma's Nerlynx

Aethlon, UPMC Land $3.5M NIDCR Grant to Explore Exosome Depleting Capability of Hemopurifier

Genetic Testing Challenges in Oncology: Assuming All Labs Are Equal Gives False Reassurance of Risk

Adaptive Biotechnologies Receives Expanded FDA Clearance for ClonoSeq MRD Assay

What's Popular?

Adaptive Biotechnologies Receives Expanded FDA Clearance for ClonoSeq MRD Assay

Roche's Rozlytrek Garners Conditional Authorization in Europe for Cancers With NTRK, ROS1 Fusions

Canbridge Pharmaceuticals Receives Marketing Approval in Taiwan for Puma's Nerlynx

Sponsorships